Ribociclib

證據等級: L5

預測適應症: 4 個

Ribociclib: From HR+/HER2- Breast Cancer to Myeloid Leukemia

One-Sentence Summary

Ribociclib is a CDK4/6 inhibitor used internationally (as Kisqali) for HR+/HER2- advanced or metastatic breast cancer, though it is not currently registered in New Zealand. The TxGNN model predicts it may be effective for Myeloid Leukemia, but this direction is currently supported only by 0 clinical trials and 3 publications, one of which reports the opposite association (AML arising after CDK4/6 inhibitor exposure).

Quick Overview

Item	Content
Original Indication	HR+/HER2- advanced/metastatic breast cancer (per literature in this evidence pack; not NZ-registered)
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.35%
Evidence Level	L4
New Zealand Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Official mechanism-of-action documentation for ribociclib is currently a data gap (DrugBank query pending, item DG002). Based on the literature within this evidence pack, ribociclib is consistently described as an oral, highly selective CDK4/6 (cyclin-dependent kinase 4/6) inhibitor that blocks cell-cycle progression via the cyclin D–CDK4/6–Rb pathway, and it is used clinically for HR+/HER2- breast cancer.

The rationale for extending this mechanism to myeloid leukemia is that the cyclin D–CDK4/6–Rb axis is also over-activated in a subset of AML blasts; one in vitro study (PMID 32560251) reports that CDK4/6 inhibitors can overcome pharmacokinetic drug resistance in AML cells, suggesting a theoretical basis for antileukemic activity.

However, this mechanistic hypothesis is directly contradicted by a second source in the same evidence set: a case report (PMID 30575100) describing a patient who developed AML with eosinophilia after CDK4/6 inhibitor treatment, consistent with the known myelosuppressive/marrow-toxicity profile of this drug class rather than a therapeutic effect. A third publication (PMID 41641105) is a case report of vulvar/breast adenocarcinoma that is largely unrelated to leukemia treatment. With no clinical trials testing ribociclib for myeloid leukemia, the evidence direction is currently ambiguous rather than supportive.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32560251	2020	Preclinical/In vitro	Cancers	CDK4/6 inhibitors may overcome pharmacokinetic drug resistance (ABCB1/ABCG2-mediated) in AML cells in vitro
30575100	2019	Case Report (adverse event)	American Journal of Hematology	AML with eosinophilia arose after CDK4/6 inhibitor treatment in a patient with underlying clonal hematopoiesis — signal of marrow toxicity, not treatment benefit
41641105	2026	Case Report (largely unrelated)	Frontiers in Oncology	Case of vulvar adenocarcinoma with concomitant breast cancer; not directly relevant to myeloid leukemia treatment

New Zealand Market Information

Ribociclib is not currently marketed in New Zealand — no product license or authorization records are available (0 licenses on file).

Cytotoxicity

Ribociclib is an antineoplastic agent (CDK4/6 inhibitor used in breast cancer treatment), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (CDK4/6 inhibitor — not a conventional cytotoxic chemotherapeutic)
Myelosuppression Risk	High — multiple pharmacovigilance and meta-analysis sources in this evidence set (e.g., hematological toxicity network meta-analysis, FAERS-based comparative studies, systematic review of CDK4/6 inhibitor hematological adverse events) consistently identify neutropenia, thrombocytopenia, and leukopenia as common, often dose-limiting toxicities of this drug class
Emetogenicity Classification	Not established from current evidence pack — refer to official package insert once obtained
Monitoring Items	CBC with differential (baseline and periodic, particularly neutrophils and platelets); liver function tests; ECG/QT monitoring should be confirmed against the label, as QT prolongation is a recognized class concern for CDK4/6 inhibitors
Handling Protection	Oral small-molecule targeted agent; institutional hazardous-oral-oncolytic handling precautions are recommended pending confirmation from the official package insert (currently a Blocking data gap, see below)

Safety Considerations

Official TFDA/NZ package insert data (key warnings, contraindications) and drug-drug interaction data are not yet available (Blocking data gap DG001) — please refer to the package insert for safety information once obtained.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for the myeloid leukemia hypothesis is preclinical-only (L4), with no clinical trials and a directly conflicting adverse-event signal (CDK4/6 inhibitor–associated AML). Combined with the drug's unregistered status in New Zealand and a Blocking safety data gap (no TFDA/NZ package insert yet obtained), the candidate cannot proceed past initial screening. Note also that other TxGNN-ranked candidates for this drug (thrombocytopenia, marcothrombocytopenia, hereditary thrombocytopenia) appear to reflect ribociclib's known myelosuppressive adverse-effect profile rather than genuine treatment opportunities — this raises a general caution about interpreting raw TxGNN scores for this drug without evidence triage.

To proceed, the following is needed:

Official TFDA/NZ package insert (warnings, contraindications) — Blocking gap DG001
Verified mechanism-of-action documentation from DrugBank — High-priority gap DG002
A dedicated preclinical/translational study to resolve the conflicting AML signal (antileukemic activity vs. drug-induced AML risk) before any clinical trial is considered
Re-triage of the thrombocytopenia-related candidates to confirm they represent ADR signals rather than repurposing opportunities, before further evaluation resources are committed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.